Michael A McDevitt
Overview
Explore the profile of Michael A McDevitt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luke J, Barlesi F, Chung K, Tolcher A, Kelly K, Hollebecque A, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33608377
Background: CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated...
2.
Oppliger Leibundgut E, Haubitz M, Burington B, Ottmann O, Spitzer G, Odenike O, et al.
Haematologica
. 2020 Aug;
106(9):2397-2404.
PMID: 32732354
In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were...
3.
Poh W, Dilley R, Moliterno A, Maciejewski J, Pratz K, McDevitt M, et al.
Clin Cancer Res
. 2019 Jan;
25(8):2513-2522.
PMID: 30692098
Purpose: Defective homologous recombination (HR) has been reported in multiple myeloid disorders, suggesting a shared dysregulated pathway in these diverse malignancies. Because targeting HR-defective cancers with PARP inhibition (PARPi) has...
4.
Norsworthy K, DeZern A, Tsai H, Hand W, Varadhan R, Gore S, et al.
Leuk Res
. 2017 Sep;
61:25-32.
PMID: 28869816
Timed sequential therapy (TST) aims to improve outcomes in acute myelogenous leukemia (AML) by harnessing drug-induced cell cycle kinetics of AML, where a second drug is timed to coincide with...
5.
Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, et al.
Oncotarget
. 2016 Dec;
8(4):6483-6495.
PMID: 28031539
Background: Deletion of chromosome 5q (del(5q)) is the most common karyotypic abnormality in myeloid neoplasms. Materials And Methods: To define the pathogenic molecular features associated with del(5q), next-generation sequencing was...
6.
Pratz K, Rudek M, Gojo I, Litzow M, McDevitt M, Ji J, et al.
Clin Cancer Res
. 2016 Aug;
23(4):899-907.
PMID: 27551000
The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia...
7.
Gojo I, Beumer J, Pratz K, McDevitt M, Baer M, Blackford A, et al.
Clin Cancer Res
. 2016 Aug;
23(3):697-706.
PMID: 27503200
Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating...
8.
Pratz K, Koh B, Patel A, Flatten K, Poh W, Herman J, et al.
Clin Cancer Res
. 2016 Mar;
22(15):3894-902.
PMID: 26979391
Purpose: DNA repair defects have been previously reported in myeloproliferative neoplasms (MPN). Inhibitors of PARP have shown activity in solid tumors with defects in homologous recombination (HR). This study was...
9.
Baerlocher G, Oppliger Leibundgut E, Ottmann O, Spitzer G, Odenike O, McDevitt M, et al.
N Engl J Med
. 2015 Sep;
373(10):920-8.
PMID: 26332546
Background: Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained...
10.
Kasamon Y, Bolanos-Meade J, Prince G, Tsai H, McCurdy S, Kanakry J, et al.
J Clin Oncol
. 2015 Aug;
33(28):3152-61.
PMID: 26261255
Purpose: Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in...